Antifungal trials complete

February 1, 2004

Waikoloa, Hawaii - A new foam formulation of the antifungal drug ketoconazole (Extina 2 percent, Connetics Corp.), currently under FDA review, seems to be more completely absorbed into the skin than the same ingredient in other formulations and could be more effective in the treatment of sehorrheic dermatitis, said Linda F. Stein Gold, M.D., director of clinical research, department of dermatology, Henry Ford Health System, West Bloomfield, Mich.